NASDAQ:INSY

INSYS Therapeutics Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.

Add

Compare

Today's Range N/A

50-Day Range

$0.23

MA: $23,687,640.18▼

$65,799,000.00

52-Week Range N/A

VolumeN/A

Average Volume9.52 million shs

Market Capitalization$21.71 million

P/E RatioN/A

Dividend YieldN/A

Beta3.21

INSYS Therapeutics (NASDAQ:INSY) Vs. COCP, REPH, ASRT, VBLT, PRPH, and CLSN

Should you be buying INSY stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to INSYS Therapeutics, including Cocrystal Pharma (COCP), Recro Pharma (REPH), Assertio (ASRT), Vascular Biogenics (VBLT), ProPhase Labs (PRPH), and Celsion (CLSN).

INSYS Therapeutics vs. Cocrystal Pharma Stock

Cocrystal Pharma (NASDAQ:COCP) and INSYS Therapeutics (NASDAQ:INSY) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Analyst Ratings

This is a summary of current ratings and recommmendations for Cocrystal Pharma and INSYS Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	0	0	2	0	3.00
INSYS Therapeutics	0	0	0	0	N/A

Cocrystal Pharma presently has a consensus price target of $4.75, suggesting a potential upside of 295.83%.

Valuation and Earnings

This table compares Cocrystal Pharma and INSYS Therapeutics' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	$6.56 million	13.07	$-48,170,000.00	($0.06)	-20.00
INSYS Therapeutics	$82.08 million	0.00	$-124,510,000.00	($1.39)	N/A

Cocrystal Pharma has higher earnings, but lower revenue than INSYS Therapeutics. Cocrystal Pharma is trading at a lower price-to-earnings ratio than INSYS Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cocrystal Pharma and INSYS Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	-2,938.09%	-25.81%	-23.98%
INSYS Therapeutics	-346.61%	-1,430.37%	-64.04%

Volatility & Risk

Cocrystal Pharma has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500. Comparatively, INSYS Therapeutics has a beta of 3.21, suggesting that its share price is 221% more volatile than the S&P 500.

Institutional and Insider Ownership

18.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 14.9% of INSYS Therapeutics shares are owned by institutional investors. 10.8% of Cocrystal Pharma shares are owned by company insiders. Comparatively, 65.4% of INSYS Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Cocrystal Pharma beats INSYS Therapeutics on 6 of the 11 factors compared between the two stocks.

INSYS Therapeutics vs. Recro Pharma Stock

Recro Pharma (NASDAQ:REPH) and INSYS Therapeutics (NASDAQ:INSY) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, dividends, earnings, institutional ownership and analyst recommendations.

Institutional & Insider Ownership

56.3% of Recro Pharma shares are held by institutional investors. Comparatively, 14.9% of INSYS Therapeutics shares are held by institutional investors. 23.1% of Recro Pharma shares are held by company insiders. Comparatively, 65.4% of INSYS Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for Recro Pharma and INSYS Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recro Pharma	0	0	2	0	3.00
INSYS Therapeutics	0	0	0	0	N/A

Recro Pharma presently has a consensus target price of $12.00, suggesting a potential upside of 334.78%.

Volatility & Risk

Recro Pharma has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Comparatively, INSYS Therapeutics has a beta of 3.21, suggesting that its share price is 221% more volatile than the S&P 500.

Valuation & Earnings

This table compares Recro Pharma and INSYS Therapeutics' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recro Pharma	$99.22 million	0.86	$-18,630,000.00	$0.20	13.80
INSYS Therapeutics	$82.08 million	0.00	$-124,510,000.00	($1.39)	N/A

Recro Pharma has higher revenue and earnings than INSYS Therapeutics. INSYS Therapeutics is trading at a lower price-to-earnings ratio than Recro Pharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Recro Pharma and INSYS Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Recro Pharma	-34.14%	N/A	-18.97%
INSYS Therapeutics	-346.61%	-1,430.37%	-64.04%

Summary

Recro Pharma beats INSYS Therapeutics on 9 of the 11 factors compared between the two stocks.

INSYS Therapeutics vs. Assertio Stock

INSYS Therapeutics (NASDAQ:INSY) and Assertio (NASDAQ:ASRT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, profitability and analyst recommendations.

Valuation and Earnings

This table compares INSYS Therapeutics and Assertio's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INSYS Therapeutics	$82.08 million	0.00	$-124,510,000.00	($1.39)	N/A
Assertio	$229.50 million	0.37	$-217,200,000.00	($3.07)	-0.16

INSYS Therapeutics has higher earnings, but lower revenue than Assertio. Assertio is trading at a lower price-to-earnings ratio than INSYS Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

14.9% of INSYS Therapeutics shares are held by institutional investors. Comparatively, 40.0% of Assertio shares are held by institutional investors. 65.4% of INSYS Therapeutics shares are held by insiders. Comparatively, 2.7% of Assertio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations and price targets for INSYS Therapeutics and Assertio, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INSYS Therapeutics	0	0	0	0	N/A
Assertio	0	0	4	0	3.00

Assertio has a consensus target price of $3.50, suggesting a potential upside of 623.44%.

Profitability

This table compares INSYS Therapeutics and Assertio's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
INSYS Therapeutics	-346.61%	-1,430.37%	-64.04%
Assertio	-145.15%	-259.36%	-55.13%

Risk & Volatility

INSYS Therapeutics has a beta of 3.21, meaning that its stock price is 221% more volatile than the S&P 500. Comparatively, Assertio has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500.

Summary

Assertio beats INSYS Therapeutics on 7 of the 11 factors compared between the two stocks.

INSYS Therapeutics vs. Vascular Biogenics Stock

INSYS Therapeutics (NASDAQ:INSY) and Vascular Biogenics (NASDAQ:VBLT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, profitability and analyst recommendations.

Valuation and Earnings

This table compares INSYS Therapeutics and Vascular Biogenics' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INSYS Therapeutics	$82.08 million	0.00	$-124,510,000.00	($1.39)	N/A
Vascular Biogenics	$560,000.00	145.42	$-19,460,000.00	($0.54)	-3.13

Vascular Biogenics has lower revenue, but higher earnings than INSYS Therapeutics. Vascular Biogenics is trading at a lower price-to-earnings ratio than INSYS Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

14.9% of INSYS Therapeutics shares are held by institutional investors. Comparatively, 4.5% of Vascular Biogenics shares are held by institutional investors. 65.4% of INSYS Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations and price targets for INSYS Therapeutics and Vascular Biogenics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INSYS Therapeutics	0	0	0	0	N/A
Vascular Biogenics	0	0	4	0	3.00

Vascular Biogenics has a consensus target price of $4.1250, suggesting a potential upside of 144.08%.

Profitability

This table compares INSYS Therapeutics and Vascular Biogenics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
INSYS Therapeutics	-346.61%	-1,430.37%	-64.04%
Vascular Biogenics	-2,692.41%	-61.77%	-47.23%

Risk & Volatility

INSYS Therapeutics has a beta of 3.21, meaning that its stock price is 221% more volatile than the S&P 500. Comparatively, Vascular Biogenics has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500.

Summary

INSYS Therapeutics beats Vascular Biogenics on 6 of the 11 factors compared between the two stocks.

INSYS Therapeutics vs. ProPhase Labs Stock

INSYS Therapeutics (NASDAQ:INSY) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, valuation, profitability and analyst recommendations.

Valuation & Earnings

This table compares INSYS Therapeutics and ProPhase Labs' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INSYS Therapeutics	$82.08 million	0.00	$-124,510,000.00	($1.39)	N/A
ProPhase Labs	$9.88 million	8.24	$-3,150,000.00	N/A	N/A

ProPhase Labs has lower revenue, but higher earnings than INSYS Therapeutics.

Volatility & Risk

INSYS Therapeutics has a beta of 3.21, meaning that its share price is 221% more volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for INSYS Therapeutics and ProPhase Labs, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INSYS Therapeutics	0	0	0	0	N/A
ProPhase Labs	0	0	1	0	3.00

ProPhase Labs has a consensus price target of $25.00, indicating a potential upside of 365.55%.

Profitability

This table compares INSYS Therapeutics and ProPhase Labs' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
INSYS Therapeutics	-346.61%	-1,430.37%	-64.04%
ProPhase Labs	-12.92%	-15.95%	-11.65%

Institutional and Insider Ownership

14.9% of INSYS Therapeutics shares are held by institutional investors. Comparatively, 3.9% of ProPhase Labs shares are held by institutional investors. 65.4% of INSYS Therapeutics shares are held by insiders. Comparatively, 29.2% of ProPhase Labs shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

ProPhase Labs beats INSYS Therapeutics on 5 of the 9 factors compared between the two stocks.

INSYS Therapeutics vs. Celsion Stock

Celsion (NASDAQ:CLSN) and INSYS Therapeutics (NASDAQ:INSY) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.

Profitability

This table compares Celsion and INSYS Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Celsion	-4,315.00%	-104.32%	-47.65%
INSYS Therapeutics	-346.61%	-1,430.37%	-64.04%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Celsion and INSYS Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celsion	0	2	0	0	2.00
INSYS Therapeutics	0	0	0	0	N/A

Celsion presently has a consensus price target of $4.00, indicating a potential upside of 277.36%.

Institutional & Insider Ownership

13.7% of Celsion shares are owned by institutional investors. Comparatively, 14.9% of INSYS Therapeutics shares are owned by institutional investors. 20.5% of Celsion shares are owned by insiders. Comparatively, 65.4% of INSYS Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Celsion and INSYS Therapeutics' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celsion	$500,000.00	159.04	$-16,850,000.00	($0.91)	-1.16
INSYS Therapeutics	$82.08 million	0.00	$-124,510,000.00	($1.39)	N/A

Celsion has higher earnings, but lower revenue than INSYS Therapeutics. Celsion is trading at a lower price-to-earnings ratio than INSYS Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Celsion has a beta of 2.42, meaning that its share price is 142% more volatile than the S&P 500. Comparatively, INSYS Therapeutics has a beta of 3.21, meaning that its share price is 221% more volatile than the S&P 500.

Summary

INSYS Therapeutics beats Celsion on 6 of the 10 factors compared between the two stocks.